Market revenue in 2023 | USD 323.2 million |
Market revenue in 2030 | USD 754.2 million |
Growth rate | 12.9% (CAGR from 2023 to 2030) |
Largest segment | Kits & reagents |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Kits & Reagents, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Lonza Group Ltd, Merck KGaA, Charles River Laboratories International Inc, Asahi Kasei Corp, Sartorius AG, Eurofins Scientific SE, PromoCell GmbH, ATCC, InvivoGen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mycoplasma testing market will help companies and investors design strategic landscapes.
Kits & reagents was the largest segment with a revenue share of 56.22% in 2023. Horizon Databook has segmented the U.S. mycoplasma testing market based on instruments, kits & reagents, services covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. market for mycoplasma testing is expected to witness lucrative growth as it is the biggest market for biotechnology & biopharmaceuticals and a leader in biopharmaceutical R&D. According to data published by PhRMA in 2018, the U.S. biopharmaceutical industry invested around USD 102 billion in R&D activities.
Furthermore, the high prevalence of chronic diseases like cancer and extensive R&D activities by regional players for developing novel cell & gene therapies are expected to fuel the demand for cell culture solutions, which will likely drive the demand for mycoplasma testing over the forecast period. As per the American Cancer Society, in 2021, around 1.9 million new cases of cancer were estimated to be diagnosed in the U.S., with over 608,570 cancer-related deaths.
In addition, following the outbreak of COVID‐19, several U.S.-based companies were involved in extensive research for the development of novel vaccines & therapeutics, driving the demand for mycoplasma testing solutions for quality control applications.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. mycoplasma testing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. mycoplasma testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account